Senseonics Holdings, Inc.
NMS: SENSLive Quote
📈 ZcoreAI Score
Our AI model analyzes Senseonics Holdings, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get SENS Z-Score →About Senseonics Holdings, Inc.
Healthcare
Medical Devices
Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. Its products include Eversense, Eversense XL, Eversense E3, and Eversense 365, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
📊 Fundamental Analysis
Senseonics Holdings, Inc. demonstrates a profit margin of -196.0%, which is below the sector average, suggesting competitive pressure.
The company recently reported 71.8% revenue growth, which is well above average for the Healthcare sector.
Return on Equity (ROE) is -168.3%, which indicates that capital utilization is currently under pressure.
At a current price of $6.68, SENS currently trades near the bottom of its 52-week range (14%), indicating potential value or weakness (Range: $5.25 - $15.74).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
✅
Revenue Growth
Excellent
🔴
Return on Equity
Weak
⚠️
Beta (Risk)
Moderate Volatility
Key Financials
Market Cap
$279.24M
Trailing P/E
--
Forward P/E
-2.54
Beta (5Y)
1.05
52W High
$15.74
52W Low
$5.25
Avg Volume
476K
Day High
Day Low